Sjogrens

#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005

Mrinalini Dey @DrMiniDey( View Tweet )

#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for #Sjogren-Neuropathy. No superiority but clinical response was more complete & longer retention numerically favouring RTX. Support trial of BCDT in SjD @RheumNow https://t.co/87e6yFMRkk

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
🔺CTD-ILD radiological signs to look out for 👀 #CTD #ILD #UIP #NSIP #Fibrosis #scleroderma #systemicsclerosis #Sjogrens #Lupus By @IlliasulK https://t.co/hHupTz0bCy

Links:

Dr Gurdeep S Dulay @gurdeep_dulay( View Tweet )
Infusion/injxn-reactions (IRRs) w/ biologics studied in 1,832 RA pts - IRRs seen in 9.7% & were signif more common w/ being younger (OR1.79), secondary Sjögren's (OR 2.17), prior leflunomide (OR 1.5); but less common w/ Abatacept (OR 0.26) & tocilizumab (OR 0.42), golimumab (OR https://t.co/IaHajITWri
Dr. John Cush @RheumNow( View Tweet )
Pope

Lessons Learned from a Lupus Registry: Two sides of one coin?

Janet Pope, MD, MPH, FRCPC

I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or

Read Article
Diabetes Prevention with Hydroxychloroquine in Sjogren’s A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/GS07GVp5pC
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Rheumatology: Believe It or Not (4/25/2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Diabetes Prevention with Hydroxychloroquine in Sjogren’s

Jack Cush, MD

A Taiwanese insurance claims analysis looked at hydroxychloroquine (HCQ) use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset

Read Article
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Cancer Survival with TNF Inhibitors (3.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
RheumNow Podcast square

ERA, APPs, & Alpha GAL (3.21.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  Listen in for 2 new case questions - Ask Cush Anything.

Read Article
2024.year.review

2024 Rheumatology Year in Review

Jack Cush, MD

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list

Read Article
Seeing Beyond the Surface: Salivary Gland Ultrasound in IgG4 Related Disease Presentation by Dr. Amy Trang at the Rheumatology Winter Clinical Symposia - Feb 2025. https://t.co/DLXKCRz3fF https://t.co/lfobyjElFG

Links:

Dr. John Cush @RheumNow( View Tweet )
BSR Guideline on Management of Sjögren disease The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease. https://t.co/UJOvb937lk https://t.co/P77h91nPuN

Links:

Dr. John Cush @RheumNow( View Tweet )
Sjogren,board

BSR Guideline on Management of Sjögren disease

Jack Cush, MD

The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease. 

This guideline is an update to the 2017 guideline and is based on medical literature review focused on 19 clinical questions. While most of the

Read Article
QD Clinic - ANA Negative Lupus Pregnant ANA negative SLE (?) patients with Sjogrens and FM - what to do? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6… https://t.co/RyCdiadn4H https://t.co/EvWcQ6KIxQ

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
eyes

Best of 2024: Diagnosing Seronegative Sjogren's Disease

Jack Cush, MD

Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy

Read Article
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled,… https://t.co/kkIOCUZRml https://t.co/nL47c5veCp
Dr. John Cush @RheumNow( View Tweet )
Phase 2b Study of Ianalumab in Sjögren's A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD). https://t.co/08W0N1f3ap https://t.co/lyZwGI56Qq

Links:

Dr. John Cush @RheumNow( View Tweet )
eyes

Phase 2b Study of Ianalumab in Sjögren's

Jack Cush, MD

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

The Phase 2b trial enrolled 190 SjD patients who were randomized (1:1:1:1) to either placebo or ianalumab (5, 50, or

Read Article
#ACR24: What I learned in Sjogren's, Takayasu's and CAR-T Dr. Janet Pope reviews abstract 2527 and abstract 1696. https://t.co/rrrGnOhfIV https://t.co/Ht1UTtYOLI

Links:

Dr. John Cush @RheumNow( View Tweet )
×